Medicinal cannabis is now routine in Australia, but almost every product is unapproved, the evidence is weak outside a few narrow uses, and THC drives most of the risk. This lesson gives learners the five levers insurers can use to manage it.
1. Treatment overview
- Two main cannabinoids. CBD is non-intoxicating. THC is psychoactive and the source of most clinical risk.
- Product types: oils, capsules, sprays, and dried flower for vaporising. Different routes give very different absorption and risk profiles. Flower is usually high in THC.
- Prescribers: doctors and nurse practitioners, increasingly through online-only telehealth clinics.
2. Current literature and evidence
- Chronic non-cancer pain: only about 1 in 22 to 26 patients get a meaningful (30 to 50%) reduction in pain. There is moderate evidence for small gains in neuropathic pain, especially MS-related pain, and insufficient evidence for arthritis or fibromyalgia.
- No consistent improvement in physical function, emotional wellbeing or quality of life, though some people report better sleep.
- Psychological conditions (anxiety, PTSD, depression, ADHD, psychosis, substance use disorders): high-quality trials show no meaningful benefit for most. There is no RCT evidence for depression.
- Adverse effects are significantly more common than with placebo: dizziness, drowsiness, cognitive impairment and mood changes. Higher-THC products carry risks of dependence, worsening psychosis and increased craving in substance use disorders.
3. Prescribing guidelines and regulation
- Only two medicinal cannabis products are fully approved on the ARTG (RACGP, February 2026). Almost everything else is supplied as an unapproved product through the Special Access Scheme or the Authorised Prescriber pathway.
- TGA data shows close to one million approvals by the end of 2025 (The Conversation, March 2026).
- Nurse practitioners can prescribe without doctor oversight, within their scope. Regulators expect a thorough assessment, monitoring and communication with the GP. "Script-only" telehealth prescribing is considered non-compliant.
- AHPRA identified practitioners writing more than 10,000 cannabis scripts each in six months, and the TGA is reviewing whether the current access pathways remain appropriate (Medical Republic). Expect changes.
4. Indications and contraindications
- Possible limited adjunct role in selected chronic and neuropathic pain, with careful monitoring. Not first-line, and should not replace standard pain treatment.
- Not supported for most psychological conditions. Established therapies such as CBT have stronger evidence.
- High-risk groups for THC: personal or family history of psychosis, substance use disorder (including alcohol), concurrent opioids or benzodiazepines, and anyone who drives or works in safety-critical roles.
5. Processes
- Access: the prescriber obtains SAS approval for the patient, or prescribes as an Authorised Prescriber. Products are almost always private scripts, not PBS.
- What to request before approving: the named product (brand, THC and CBD content, dose), the access pathway, the condition being treated, other medicines and substance history, and measurable goals.
- A structured trial: baseline pain, function, sleep and work capacity, then review at 3 months. If meaningful benefit isn't shown, treatment ends.
6. What it means for you
| Role | What to do |
|---|---|
| Case manager or IMA | Use the five levers below. Approve named products, never open access to a clinic's catalogue. Check the dispensed product matches what was approved, especially THC versus CBD. |
| Rehab provider | Record function at baseline and at 3 months. Watch for sedation, low motivation, worsening anxiety or paranoia, and report it. |
| WHS officer | THC with any driving is a High profile, so driving is Red until cleared. Any THC product on another Tier 3 task needs written functional advice first, even on a Low profile. Driving with detectable THC is an offence in most states even with a prescription; check the current rules in your state. Connect cannabis declarations to your drug testing process. |
The five insurer levers, light-touch to firm
- Approve specific products only
- Provisional, time-limited approval with review built into the next claim cycle
- A three-month controlled trial with defined outcome measures
- Refer for an independent pharmacist review before approving
- Decline where the risks are significant